A Response to: Letter to the Editor Regarding "Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants".

Autor: Perdrizet J; Global Health Economics and Outcomes Research, Pfizer Inc., 235 42nd Street, New York, NY, 10017, USA. johnna.perdrizet@pfizer.com., Horn EK; Global Health Economics and Outcomes Research, Pfizer Inc., 235 42nd Street, New York, NY, 10017, USA., Nua W; Pfizer Inc., Makati City, Philippines., Perez-Peralta J; Pfizer Inc., Makati City, Philippines., Nailes J; Research Institute for the Health Sciences, University of the East Ramon Magsaysay Memorial Medical Center, Quezon City, Philippines., Santos J; Infectious Diseases Section, Philippine Children's Medical Center, Quezon City, Philippines., Ong-Lim A; Infectious and Tropical Disease, Department of Pediatrics, College of Medicine-Philippine General Hospital, University of the Philippines, Manila, Philippines.
Jazyk: angličtina
Zdroj: Infectious diseases and therapy [Infect Dis Ther] 2022 Jun; Vol. 11 (3), pp. 1301-1303. Date of Electronic Publication: 2022 Apr 26.
DOI: 10.1007/s40121-022-00639-3
Abstrakt: This communication seeks to address the questions of Dhere and colleagues in their letter on our study "Cost-effectiveness of the 13-valent pneumococcal conjugate vaccine (PCV13) versus lower-valent alternatives in Filipino infants." We hope to provide clarity on each of the three potential misunderstandings of our cost-effectiveness analysis that were raised by Dhere and colleagues.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje